Pay in 4 interest-free payments of $5.24 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Instead, gently roll the vial between your palms or invert it slowly a few times
Remember to keep the cap on the pen to protect the medicine from light
CagriSema's Advantages: First to Market: 6-12 month head start Leverages Wegovy Success: Built-in brand recognition Proven Semaglutide Component: Half the drug is already approved Strong Diabetes Data: Positions for dual indication No Dysesthesia: Cleaner safety profile in one key area Retatrutide's Advantages: Higher Efficacy: 28.7% vs 20.4% (8.3 points more) Superior BP Reduction: -14 mmHg vs likely similar to semaglutide Single Molecule: Potentially easier manufacturing Multiple Indications: OA, OSA, obesity, diabetes trials Novel Class: First triple agonist = strong IP protection The Verdict: Market Will Support Both These medications won't compete head-to-head
If you need to increase your dose, switch medications, or pause treatment, you communicate through the platform messaging system
Even among patients with diabetes, where the clinical case for continued treatment was strongest, 46.5 percent stopped within 12 months
US$ 23.37
US$ 23.37
US$ 27.49
US$ 28.21
